Install
- 174articles · 90d
- 2+ day agolatest article
- Jun 15, 2026earliest in window
- 52%with images
- 269avg words
- Medical 153
- Health & Wellness 147
- Health 120
- Education 23
- Science & Technology 10
- Jobs & Education 9
- Disaster, Accident & Emergency Incident 8
- Education & Jobs 7
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Statin-Specific Effects May Influence Immunotherapy Outcomes in Patients With Head and Neck Squamous Cell Carcinoma
3+ day, 7+ hour ago (358+ words) Allen Khudaverdyan, MD, NYU Grossman School of Medicine, New York, New York, discusses results from a large retrospective analysis evaluating the association between concurrent statin use and overall survival in patients with head and neck squamous cell carcinoma treated with…...
FDA Approves Camizestrant Plus CDK4/6 Inhibitor Following Emergence of ESR1 Mutation in Advanced Breast Cancer
4+ day, 11+ hour ago (273+ words) Based on results from the phase 3 SERENA-6 trial, the US Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah; AstraZeneca) in combination with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer following detection…...
FDA Approves Zanidatamab-Based Regimens for First-Line HER2-Positive Advanced Gastroesophageal Adenocarcinoma
2+ week, 4+ day ago (192+ words) The approval of zanidatamab plus tislelizumab and chemotherapy applies to patients with HER2 IHC 3+ or IHC 2+/ISH+ tumors, while zanidatamab plus chemotherapy without tislelizumab is approved for patients with HER2 IHC 3+ disease. HER2 positivity must be confirmed using an FDA-approved test. PFS was…...
Recurrent Inflammatory Plaques on Upper Extremities in a Patient With Breast Cancer Surgery History
1+ mon, 1+ week ago (156+ words) Although also unnecessary for diagnosis, a negative keratin stain would be expected. A keratin stain was performed in this case, and its negative result was interpreted to exclude carcinoma as a possible differential diagnosis. This patient was managed with a…...
ctDNA MRD Testing in Lymphoma: What It Is and How It Works
2+ mon, 5+ day ago (520+ words) HMP Global Learning Network Some of the data collected by this provider is for the purposes of personalization and measuring advertising effectiveness. - h415.hmpgloballearningnetwork.com 2 AWSALB [x2]Registers which server-cluster is serving the visitor. This is used in context with load balancing,…...
Vepdegestrant Improves Outcomes in ESR1-Mutant ER-Positive Metastatic Breast Cancer
2+ mon, 1+ week ago (507+ words) HMP Global Learning Network Vepdegestrant Improves Outcomes in ESR1-Mutant ER-Positive Metastatic Breast Cancer - Design/Population: The phase 3 VERITAC-2 trial randomized patients with ER-positive, HER2-negative metastatic breast cancer who had progressed on a CDK4/6 inhibitor to receive either vepdegestrant or fulvestrant. The…...
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
2+ mon, 2+ week ago (16+ words) HMP Global Learning Network...
Pembrolizumab Demonstrates Long-Term Survival Benefit in in Early-Stage Triple-Negative Breast Cancer
2+ mon, 2+ week ago (24+ words) HMP Global Learning Network Insights from the ASCO Annual Meeting...
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
2+ mon, 2+ week ago (246+ words) Dr Schmid presented these results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. I'm Peter Schmid, I'm a medical oncologist and work at Barts Hospital in London. I had the pleasure of presenting data from…...
Frontline Sacituzumab Govitecan Continues to Show Benefit in PD-L1–Positive Triple-Negative Breast Cancer
2+ mon, 2+ week ago (247+ words) Dr Kalinsky presented these results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The intent of reporting these new data was to look at PFS2, because the overall survival data remain immature. We are still awaiting…...